American Cell Therapies Company Selects ValGenesis VLMS to Digitize Multiple Validation Lifecycle Processes
News provided by
Share this article
Share this article
SAN FRANCISCO, Jan. 25, 2021 /PRNewswire/ ValGenesis Inc., a market leader in Enterprise Validation Lifecycle Management Solutions (VLMS), today announced that a U.S. based cell therapies company has selected ValGenesis VLMS – the industry s most trusted electronic validation lifecycle management system – to digitize multiple corporate validation lifecycle processes across the organization. The company develops novel allogeneic living drugs for oncology that overcome the limitations of first-generation cell therapies.
As a fast-growing organization with limited resources, the company is looking to the user-friendly ValGenesis VLMS to help them plan, define, and manage all validation operations, ensuring that the right amount of validation is applied to every system and asset being validated. ValGenesis VLMS will
ValGenesis Collaborates with Biocon Biologics for Digital Validation Across Multiple Sites
News provided by
Share this article
Share this article
SAN FRANCISCO, Dec. 15, 2020 /PRNewswire/ ValGenesis Inc., a market leader in Enterprise Validation Lifecycle Management Solutions (VLMS), today announced that the Equipment Commissioning and Qualification (C&Q) process (validation life cycle) at Biocon Biologics has been digitized leveraging the power of ValGenesis VLMS – the industry s most trusted electronic validation lifecycle management system. Biocon Biologics, a subsidiary of Biocon, is an integrated pure play biosimilars organization addressing patients needs across the world, including developed markets like the U.S., Canada, EU and Australia, through its partners.